

We want to save patients with severe cancer and autoimmune diseases Entering clinical phase with our lead antibody CAN04 to our proprietary target

Göran Forsberg, CEO



#### Safe Harbour Statement

The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia's current thinking with respect to future events and financial performance. Prospective statements only express the assessments and assumptions the company makes at the time of the presentation. These statements are wellconsidered, but the audience should note that, as with all prospective assessments, they are associated with risks and uncertainties.



## CANTOS IL-1ß blockade - Recent strong clinical data

#### **CANTOS trial**

- Canakinumab (Novartis)
- 10 061 patients
- Designed to reduce cardiovascular events in patients with previous myocardial infarction
- Reduced lung cancer incidence by 67 % and death by 77 %.
- Clinical validation of IL-1 pathway
- Novartis to start 3 phase 3 trials in NSCLC
- Cantargia's CAN04 has broader MOA

#### CANTOS: Additional Non-Cardiovascular Clinical Benefits Incident Lung Cancer





### CAN04 vs Canakinumab



#### Canakinumab

 Antibody directed against one of the two IL-1 ligands, IL-1β

#### **CAN04:**

- Binds the common signaling
  receptor and counteracts both
  ligands
- Induce killing via the immune system (ADCC)



## Medical need and IL1RAP



- Based on in house data, external data, medical need and market size, NSCLC and pancreatic cancer are primary indications.
- Biomarker studies ongoing, to identify patients most likely to respond
- Low levels of IL1RAP in normal tissue (analyzed following FDA and EMA guidelines)

Size of each indication corresponds to annual deaths in USA



## Cantargia at a glance

- Specialized in antibody therapy/immunology, with initial focus on oncology
- Granted IP around therapeutic target and drug candidate
- Lead antibody CAN04 in clinical development
- Strong management team with proven track record in clinical development and business development
- IPO March 2015 (Nasdaq First North, Stockholm), preparations for listing on main market ongoing
- More than 3000 shareholders
- Based in Lund, Sweden

#### **Financial highlights**

- Share price: 13.90 SEK (1.59 USD), May 9, 2018
- Market cap: 920 MSEK (105 MUSD), May 9, 2018
- Cash: 269.8 MSEK (32.7 MUSD), Dec 31 2017

Current owners (Mar 31, 2018)

Sunstone	9.0%
1st AP fund	6.9%
Avanza Pension	6.2%
4th AP fund	4.6%
SEB S.A. clients	3.7%
2nd AP fund	3.3%
Tibia konsult	2.1%
Mats Invest AB	2.0%
Kudu AB	1.9 %
Brushamn Invest	1.9%
Nordnet Pension	1.7%
SHB Pharm Fund	1.5%
Others	55.1%

## Cantargia pipeline





## Lead project CAN04 in the highest growth segment– Oncology antibodies



World's most sold cancer drugs are antibodies 2017 (2016)

Immuno-oncology driving market growth 2017 (2016)

Rituxan/MabThera	\$7.87bn	(\$8.58bn)
Avastin	\$7.13bn	(\$6.75bn)
Herceptin	\$7.47bn	(\$6.75bn)

Source IMS Health & company reported sales

Opdivo	\$4.95bn	(\$3.77bn)
Keytruda	\$3.81bn	(\$1.40bn)



# CAN04 - immuno-oncology mechanism with antitumor effect



- Antitumor effects in NSCLC PDX models
- CAN04 stimulates immune cells to infiltrate tumor
- (CAN04 not cross reactive with mIL1RAP)



# Inhibition of metastases (tumor cells with low IL1RAP)

Primary tumor

Lung metastases





### Inflammation and metastasis

- Cancer cells (seeds) needs a good soil to form a metastasis
- The IL-1 system (inflammation) can provide such environment (soil)
- Cantargia antibody block metastases (presented at American Association of Cancer Research April 16)





A tumor can create its own "seed and soil"



#### **CANFOUR clinical trial**

#### **Coordinating Investigator**:

Professor Ahmad Awada Jules Bordet Institute, Brussels, Belgium

<b>Belgium</b> Institut Jules Bordet, Brussels Contact: Dr Christiane Jungels	Recruiting
<b>Denmark</b> Rigshospitalet, Department of Oncology, Copenhagen Contact: Dr Morten Mau Sørensen	Recruiting
<b>The Netherlands</b> Netherlands Cancer Institute, Amsterdam Contact: Prof Dr Jan H.M. Schellens	Recruiting
Erasmus MC, Rotterdam Contact: Dr Ferry ALM Eskens	Recruiting
Norway	

Recruiting

Oslo University Hospital, Radiumhospitalet, Oslo Contact: Dr Tormod Kyrre Guren

Norway Scotland Edinburgh Denmar North Sea United rish Sea Kingdom Netherlands Berlin\_ Wales England Germany Belgium Paris France

## CANFOUR

#### Part I

- NSCLC, PDAC, CRC, TNBC
- Safety and tolerability
- Pharmacokinetics
- Biomarkers
- Efficacy
- Identify RP2D

#### Part II

- NSCLC, PDAC
- Safety and tolerability
- Pharmacokinetics
- Biomarkers
- Efficacy
  - Monotherapy
  - Combination SoC



Patients will stay on treatment until disease progression, unacceptable toxicity, or discontinuation for any other reason

## **CANTOS additional findings**

CANCER decreased risk of death with treatment (high dose)					
Lung cancer	77 %	P=0.0002			
Non-lung cancer	37 %	P=0.06			
Decreased incidence of inflammatory disease (all doses)					
Arthritis	32%	p<0.0001			
Ostheoartritis	28%	P=0.0005			
Gout	53%	p<0.0001			
Biomarker levels (reduction)					
CRP	26-41%	P<0.0001			
IL-6	25-43%	P<0.001			



## IL1RAP - additional potential indications to leverage the value of our asset

- Three different systems signal through IL1RAP
- These systems contribute to various inflammatory diseases
- Can be blocked by Cantargia's antibodies against IL1RAP



Cantargia partnership with Panorama Res Inc (Sunnyvale, CA) Selection of clinical candidate 2019



## Significant value inflection points ahead

#### 2018

- Preclinical data on combination therapy
- Clinical progress
- Preclinical studies
- Phase I clinical data (summer 2018)
- Initiation of Phase IIa portion of the clinical trial (summer 2018)
- US regulatory and clinical strategy
- Application for listing on main market



### Cantargia IP

Use of IL1RAP as target for hematological cancers

Valid to 2030

Granted (EPO, USA, Japan, China)

Use of IL1RAP as target for solid tumors Valid to 2032 Granted (EPO, Japan, USA, China)

The product candidate CAN04

Valid to 2035

Granted EPO, USA

New IL1RAP antibodies (e.g. CAN03) Filed 2014



### Cantargia summary

- Focus on immuno-oncology the strongest growing pharmaceutical segment
  - Taking advantage of established antibody technology to design novel pharmaceuticals
- Lead candidate antibody CAN04 in clinical trial
  - Double mechanism of action
  - Initial development in NSCLC and pancreatic cancer (cancer forms with poor prognosis)
  - Direct effects on tumor cells and tumor microenvironment
  - Recent external validation of pathway
- Second generation antibodies for autoimmune disease
- Unique and strong IP
- Strong lead investors with high competence and well known track record
  - Funding through phase IIa until mid 2020.
- Preparations for listing on main market

